<DOC>
	<DOCNO>NCT02944604</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety PEG-rhG-CSF patient breast cancer treat intensive chemotherapy prevention neutrophil reduction .</brief_summary>
	<brief_title>The Efficacy Safety PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor ) Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1.1865 year old , gender limit . 2.Breast cancer diagnose pathology . 3.Did receive chemotherapy previously plan receive 4 cycle intensive EC ( epirubicin , cyclophosphamide ) treatment . 4.No obvious blood system disease , ANC ( absolute neutrophil count ) ≥ 1.5 × 10^9/L , PLT（Platelet）≥80×10^9 /L , Hb（hemoglobin）≥75g/L , WBC（White blood cell ）≥3×109/L , bleed tendency . 5.KPS ( Karnofsky performance status ) score≥70 . 6.Expected survival≥3 month . 7.Written informed consent acquire . 1 . Severe uncontrolled infection . 2 . Sensitive product genetically engineer biological product Escherichia coli strain . 3 . Mental nervous system disorder . 4 . Severe heart , lung central nervous system disorder . 5 . Pregnant lactating woman . 6 . TBIL ( total bilirubin ) , ALT（alanine aminotransferase） , AST（glutamicoxalacetic transaminase） &gt; 2.5×ULN（upper limit normal） ; cause liver metastasis , TBIL , ALT , AST &gt; 5×ULN . 7 . Cr（creatinine） &gt; 1.5×ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>